FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
Calyxo Raises $32.7 Million in Series C Financing
Calyxo notes the investment round will fund further product development and expansion of their Team.
PhysioMedics Poised for Growth Through Capital Fundraise Following CEO Appointment
Edinburgh-based PhysioMedics secured equity and grant funding totalling £1.5m from Archangels, Scottish Enterprise and Innovate UK.
Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing
Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon in de-novo coronary artery disease lesions notes Advanced NanoTherapies.
Centerline Biomedical Raises $33 Million in Series B Financing
Centerline Biomedical notes their flagship product, IOPS® (Intra-Operative Positioning System) was developed in Cleveland Clinic's Heart and Vascular Institute and utilizes patented algorithms to generate a patient-specific vascular map combined with electromagnetic tracking and smart sensor-equipped surgical devices to provide real-time, 3-D color visualization and navigation of the human vascular system.
MicroTransponder Raises $53M
MicroTransponder plans to use the funds to commercialize the Vivistim® Paired VNS™ System and establish it as the recommended rehabilitation intervention for stroke survivors working to improve their quality of life through more hand and arm mobility.
Artio Medical Closes $28M in Additional Series A Financing
Artio Medical notes the funds will be used to support US commercialization efforts for the recently cleared Solus Gold™ Embolization Device and to accelerate the development of Artio's broad portfolio of products.